Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study

Ye, Peipei; Pei, Renzhi; Wang, Tiantian; Cao, Junjie; Zhang, Pisheng; Chen, Dong; Liu, Xuhui; Du, Xiaohong; Li, Shuangyue; Tang, Shan-Hao; Hu, Youqian; Jiang, Lei; Lu, Ying

doi:10.1007/s00277-022-04877-w

Cited by 5 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,9 However, recent reports of olanzapine-induced reductions in delayed-phase CINV warrant additional studies to combine NEPA and olanzapine to test whether delayedphase efficacy benefits would counterbalance sedating adverse effects. 17,23 Apolito et al studied NEPA in 70 multiple myeloma patients after treatment with the two-day high-dose melphalan regimen. 24 The investigators defined CR as the absence of emesis and rescue medications post-infusion for 120 h. They found a CR rate of 83% (66/80 procedures), with a large percentage of patients (98%) reporting lack of emesis and nausea with a significant percentage of patients free from nausea (78%) during the acute phase.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…1,9 However, recent reports of olanzapine-induced reductions in delayed-phase CINV warrant additional studies to combine NEPA and olanzapine to test whether delayed-phase e cacy bene ts would counterbalance sedational adverse effects. 17,23 Apolito et al (2020) studied NEPA in 70 multiple myeloma patients after treatment with the two-day highdose melphalan regimen. 24 The investigators de ned CR as the absence of emesis and rescue medications post-infusion for 120 hours.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation

Bubalo

Radke

Bensch

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective: The purpose of this study was to investigate the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of chemotherapy-induced nausea and vomiting (CINV) for hematopoietic cell transplantation (HCT) patients receiving BEAM therapy. Study Design: This phase II, prospective, intention-to-treat, single-center, single-arm study involved 43 adult patients who received NEPA and dexamethasone for the prevention of CINV due to BEAM conditioning chemotherapy. An interim analysis, performed after 13 patients, determined utility versus futility, and supported continuation to full enrollment. Descriptive statistics were used to report complete response (CR), complete protection, incidence of emesis, and administration of rescue agents. A Kaplan–Meier curve depicted time to first emesis and first rescue medication. Patients self-reported levels of daily nausea descriptively via a CINV Questionnaire. Results: By study end, 13 of 43 patients achieved a CR with an average of 10.6 emesis-free days (SD 0.95) over the 11-day observation period, with no emetic events in any patient during the acute/chemotherapy phase. Nausea was well-controlled throughout the acute therapy phase (Day 1–6) and increased during the delayed phase (Day 7–11) with a peak mean level of 2.79/10 at Day 10. Aside from lower grade (≤2), headaches, constipation, and diarrhea were the most widely reported adverse effects. Conclusion: The combination of NEPA and dexamethasone is safe and effective for the prevention of CINV in patients receiving BEAM conditioning therapy prior to HCT. The regimen demonstrated greater effectiveness in the acute phase versus the delayed phase, with low levels of nausea throughout the study period and complete emesis prevention during chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation

Bubalo

Radke

Bensch

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Although CR rates are comparable in the acute phase, significantly more patients treated with FTO achieved CR in the delayed phase (74% versus 38%, P < 0.001). 66 …”

Section: Prevention Of Nausea and Vomiting In Patients Treated With H...mentioning

confidence: 99%

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Herrstedt,

Clark-Snow,

Ruhlmann

et al. 2024

ESMO Open

View full text Add to dashboard Cite

“…В связи с этим в комбинации с апрепитантом доза дексаметазона должна быть снижена приблизительно на 50 %. У пациентов, получающих варфарин, необходимо дополнительно контролировать уровень МНО [87][88][89][90][91][92]. Антагонисты NK1-рецепторов применяют в комбинации с ГКС и антагонистами 5-НТ3-рецепторов.…”

Section: антагонисты Nk1-рецепторовunclassified

Сопроводительная Терапия При Множественной Миеломе: Практические Рекомендации

Соловьев,

Соловьева,

Менделеева

2024

Clinical Oncohematology

View full text Add to dashboard Cite

Supportive therapy is becoming increasingly important for the state-of-the-art algorithm of multiple myeloma (MM) treatment. The introduction of innovative drugs and transplantation methods into clinical practice considerably improved the disease-free and overall survival rates. However, in the vast majority of cases, MM still remains an incurable malignant plasma cell tumor. It is often treated on a continuous basis with a succession of targeted drugs and integration of glucocorticosteroids and conventional cytostatic agents into the program therapy. All of these together with immunodeficiency, bone lesions, and myeloma nephropathy lead to a high risk of adverse events and cumulative toxicity of treatment. At the same time, one of the main goals at all MM therapy stages is to maintain quality of life. The characteristics of clinical symptoms, the nuances of targeted therapy and chemotherapy-associated adverse events justify the need for further development of supportive MM therapy algorithms which remain to be a matter of current concern. They should be mainly aimed at preventing the therapy complications, reducing the rate of adverse events and clinical manifestations of side effects as well as developing a treatment strategy for cumulative toxicity. In the state-of-the-art algorithm of program MM treatment, supportive therapy-related knowledge is of no less value than the information on antitumor drugs and their efficacy. This paper reports the personal experience and provides recommendations mostly based on the results of clinical studies or views of expert panels. It also offers practical recommendations for supportive therapy in symptomatic MM which include prevention of skeletal complications, thromboses, and infections, nausea and vomiting management, vaccination, pre-medication and the algorithm of monoclonal antibody administration, anesthesia, peripheral polyneuropathy treatment, correction of secondary immunodeficiency, nutritional support, fatigue assessment and countermeasures.

show abstract

Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study

Cited by 5 publications

References 20 publications

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Сопроводительная Терапия При Множественной Миеломе: Практические Рекомендации

Contact Info

Product

Resources

About